Revolution Medicines
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Revolution Medicines sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Revolution Medicines: 16 sponsored US clinical trials, 11 recruiting.
Revolution Medicines sponsors 16 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 3 completed. 5 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-small Cell Lung Cancer (NSCLC), with 7 trials.
Top-decile sponsor footprint
Revolution Medicines ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
16 total, page 1 of 1
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
NCT03989115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 1 |
| Phase 3 | 5 |
What is open in the Revolution Medicines pipeline
11 recruiting of 16 indexed (69% open); 3 completed (19%).
Phase mix: 5 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Non-small Cell Lung Cancer (NSCLC) (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Revolution Medicines: open-pipeline peers nationwide
Peers matched on 16 registered trials and 69% open enrollment, not the therapeutic-area sidebar.
Revolution Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 69% open enrollment (± trial volume)
- CorEvitas · 69% recruiting · 13 trials
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
Related
What to do with this Revolution Medicines page
16 registered trials is a research-attention snapshot, not an endorsement of Revolution Medicines or any single study.
- 11 of Revolution Medicines's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-small Cell Lung Cancer (NSCLC) is the condition Revolution Medicines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-small Cell Lung Cancer (NSCLC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Revolution Medicines pipeline card: 16 registered trials from official public datasets.Report a data error.